Specialty Natural Products Public Company LimitedSET: SNPS🇹🇭 TH

Business Operation · 2025

Corporate Information

Company Name

Specialty Natural Products Public Company Limited

Telephone

0-3845-8698

Website

www.snpspcl.com

Email

secretary@snpthai.com

Dividend Policy

Dividend Policy

The Board of Directors may consider the payment of annual dividends of the Company, subject to approval by the shareholders’ meeting, except for interim dividends which the Board of Directors has the authority to approve from time to time when the Company has sufficient profits to do so, and shall report such payment to the shareholders’ meeting at the next meeting.

The Company has a policy to pay dividends to shareholders at a rate of not less than 30% of net profit from the separate financial statements after deduction of corporate income tax and all statutory reserves as prescribed by law and the Company’s Articles of Association, provided that the Company has no accumulated losses. The Board of Directors shall consider dividend payments taking into account various factors for the benefit of shareholders, such as economic conditions, operating results and financial position of the Company, cash flows of the Company, annual investment plans of the Company, the necessity of capital for future business expansion, reserves for loan repayment or working capital within the Company, conditions and restrictions under loan agreements, and that the dividend payment shall not have a material adverse impact on the normal operations of the Company, as necessary, appropriate, and as the Board of Directors deems fit.


https://www.snpspcl.com/en/dividend-policy-payment/

Historical Dividend Payments

This YearLast Year2 Years Ago3 Years AgoMetricDescription
0.280.260.120.42Net profit per share (Baht : Share)Net profit per share (baht : share)
0.20.2901.75Dividend per share (Baht : Share)Dividend per share (baht : share)
0000Dividend stock ratio (Number of original shares: dividend shares)Ratio of stock dividend payment (existing share : stock dividend)
0000Dividend share value per share (Baht : Share)Value of stock dividend per share (baht : share)
0.20.2901.75Total dividend payment value (Baht : Share)Total dividend payment (baht : share)
7.4111.620420.26Dividend payout ratio to net profit (%)Dividend payout ratio compared to net profit (%)

Major Shareholders

Major Shareholders

No.NameShares% Shares
25,218Specialty Natural Innovation Co., Ltd.147,999,98036.54
25,219Mrs. Panvipa Krisdaphong87,174,53021.53
25,220Ms. Theeraya Krisdaphong64,825,49016.01
25,221Mrs. Pimonlak Tantisak16,060,4003.97
25,222Mr. Thanat Tatayannon15,545,8003.84
25,223Mr. Kajonwat Wattanaporn15,542,9003.84
25,224Ms. Sarannuch Panyaworakunachai14,762,1003.65
25,225Bangkok Chain Management Co., Ltd.12,000,0002.96
25,226Ms. Thitapha Wattanaporn3,579,0000.88
25,227Karmarts Public Company Limited3,000,0000.74

Business Strategies Overview

Chairman's Message

Over the past several years, Specialty Natural Products Public Company Limited (“SNPS” or the “Company”) has continuously developed and deepened its expertise in Thai botanicals and natural resources, establishing itself as an integral part of the global health and beauty industry supply chain, amidst rapidly evolving economic conditions, technological advances, and rising stakeholder expectations.

The Board of Directors recognizes the importance of establishing clear, prudent, and adaptable strategic direction for long-term success. Accordingly, the Board has endorsed a strategic framework for the period 2026–2028, focusing on quality-driven growth, enhanced competitiveness, and responsible business operations with due regard for society and the environment.

The Company’s strategy is anchored in the principle of elevating Thai botanicals to international standards through its 4C innovation framework: developing raw materials from upstream sources (Cultivation), generating innovation and knowledge through research (Creation), transforming outputs into value-added products and solutions (Conversion), and sharing value with stakeholders throughout the value chain (Contribution).

Under the 2026–2028 strategic plan, the Company’s priorities include expanding into international markets and increasing the share of export revenue, enhancing operational efficiency and profitability, generating revenue from innovation and intellectual property, and embedding Environmental, Social, and Governance (ESG) considerations into policy-making and business decisions at all levels.

The Board of Directors firmly believes that sustainable growth cannot be achieved through short-term performance alone; it requires a foundation of sound corporate governance, prudent risk management, continuous human capital development, and value co-creation with farmers, business partners, communities, and all stakeholders.

On behalf of the Board of Directors, I would like to express our sincere gratitude to shareholders, customers, business partners, employees, and all stakeholders for their continued support and trust in the Company. The Board remains committed to overseeing and supporting management in achieving the Company’s strategic objectives and delivering stable, transparent, and sustainable long-term growth.

Vision

“We are committed to setting new standards for regional botanicals on the global stage, to sustain human health and planetary well-being.”

The Company is dedicated to elevating regional botanicals and natural resources to international standards through research, development, and sourcing of natural ingredients supported by scientific evidence, in service of the health and beauty industry and human well-being, coupled with responsible resource utilization and environmental stewardship.

The Company aspires to be a leading developer and supplier of natural ingredients in the Asian region, operating under the principles of ethics, transparency, and good corporate governance to deliver appropriate and sustainable returns for shareholders while maintaining a balanced responsibility toward society, the environment, and all stakeholders.

Objectives

“Partnering with Nature, Empowering Growth”

  1. Achieve continuous and stable growth in operating results based on an efficient business structure capable of long-term competitiveness, and support the commercialization of local wisdom to create sustainable economic value.

  2. Develop high-value-added natural products and innovations by integrating local wisdom with scientific research and technology to elevate Thai botanicals and natural resources to international standards.

  3. Conduct business with integrity, transparency, and good governance, respecting the rights of shareholders, customers, business partners, employees, and all stakeholder groups, to build confidence and sustainability in long-term operations.

  4. Minimize environmental impact and promote efficient resource utilization throughout the value chain—from raw material sourcing and manufacturing to product delivery—to support balanced growth across economic, social, and environmental dimensions.

  5. Strengthen organizational capabilities to adapt to changes in the business environment, regulations, technology, and market expectations, in support of growth in an increasingly sustainable and responsible global economy.

Goals

The Company operates under its proprietary 4C framework—Cultivation, Creation, Conversion, and Contribution—a value creation model spanning the entire business chain from upstream to midstream to downstream. This framework is designed to elevate Thai botanicals and natural resources to international standards through research, development, and innovation supported by scientific evidence, in conjunction with responsible business practices toward society, the environment, and all stakeholders.

1. Cultivation (Develop)

Develop quality raw materials from upstream by collaborating with farmers and community networks to upgrade herbal cultivation processes to meet appropriate quality, consistency, and certification standards, thereby securing stable raw material sources and reducing long-term supply chain risks.

2. Creation (Innovate)

Develop innovative herbal extracts and active ingredients through research, science, and technology, in collaboration with research institutions and partners both domestically and internationally, to enhance product quality, efficacy, and compliance with international standards.

3. Conversion (Commercialize)

Transform developed knowledge and extracts into value-added products, both as ingredients for customers and as finished products under the Company’s own brands, to expand business opportunities and access domestic and international markets effectively.

4. Contribution (Create Shared Value)

Create shared value for all stakeholders through knowledge dissemination, capacity building for farmers and communities, efficient resource utilization, and ethical business practices, to support sustainable growth at both the organizational and societal levels.

Business Strategies

The Company has formulated its business strategies for the period 2026–2028 to support sustainable growth, enhanced competitiveness, and long-term value creation for shareholders and stakeholders. The strategy is organized around four pillars:

Strategy 1: Global Market Leadership and Export Expansion

The Company aims to strengthen its position in international markets by broadening its customer base and progressively increasing the share of export revenue, while enhancing the reputation and competitiveness of its natural ingredient products to become a leading natural ingredient supplier in Southeast Asia.

Key implementation approaches:

  1. Develop products aligned with international standards and customer requirements.

  2. Expand collaboration with international business partners and distributors.

  3. Increase the share of export revenue and diversify geographic market exposure.

Strategy 2: Operational Excellence and Profitability Enhancement

The Company aims to enhance operational efficiency throughout the value chain—from raw material sourcing and manufacturing to product delivery—with emphasis on shifting the product portfolio toward higher-margin categories and improving resource utilization efficiency to reduce costs and increase profitability.

Key implementation approaches:

  1. Increase the share of premium herbal products and direct material (DM) solutions in the revenue mix.

  2. Improve production process efficiency and eliminate hidden costs.

  3. Manage and control expense growth in alignment with sustainable EBITDA growth targets.

  4. Add value to domestically sourced raw materials to meet international market demand.

Strategy 3: Innovation Ecosystem and IP Monetization

The Company aims to generate growth through innovation and knowledge by systematically developing and managing intellectual property to create new revenue streams and enhance long-term competitiveness.

Key implementation approaches:

  1. Establish and develop the Company’s innovation ecosystem.

  2. Develop new formulations and technologies eligible for patent protection and commercial application.

  3. Generate revenue from licensing, co-development, and technology transfer arrangements.

  4. Bridge research outputs from domestic and international institutions to commercial deployment.

Strategy 4: ESG Leadership and Regenerative Impact

The Company embeds Environmental, Social, and Governance (ESG) considerations into strategic planning and business decision-making at all levels, with the aim of reducing environmental impact, strengthening farming communities, and elevating corporate governance standards to internationally recognized benchmarks.

Key implementation approaches:

  1. Increase the use of renewable energy and reduce greenhouse gas (GHG) emissions in Scope 1 and Scope 2.

  2. Develop and implement science-based carbon reduction plans for Scope 3 emissions.

  3. Expand the herbal farmer network and promote responsible agricultural practices.

  4. Establish and maintain ESG ratings at appropriate levels according to international benchmarks.

The 2026–2028 business strategies are designed to achieve a balanced approach across economic growth, competitiveness, innovation, and sustainability, enabling the Company to grow steadily over the long term and create enduring value for shareholders and all stakeholders.

Material Changes & Developments

Material Changes & Developments

YearDescription
1,999
  • Incorporated Specialty Natural Products Co., Ltd. (“SNPS”) with THB 5,000,000 registered capital on 29 September 1999, to engage in the manufacturing and distribution of standardized Thai herbal extracts for use in cosmetics, cosmeceuticals, and dietary supplements.

2,000
  • SNPS increased registered capital by THB 35,000,000, from THB 5,000,000 to THB 40,000,000, by issuing 3,500,000 new ordinary shares at THB 10 par value for working capital.

  • SNPS received a BOI investment promotion certificate for the production of raw materials for cosmetics under Category 6.11 (Other Chemical Products). Tax benefits expired in 2007.

2,001
  • SNPS received BOI investment promotion certificates for the production of raw materials for cosmetics and herbal plant extracts under Category 1.20 (Herbal Plant Products) and Category 6.11 (Other Chemical Products). Tax benefits expired in 2008.

2,002
  • SNPS increased registered capital by THB 4,000,000, from THB 40,000,000 to THB 44,000,000, by issuing 400,000 new ordinary shares at THB 10 par value for working capital.

2,003
  • SNPS increased registered capital by THB 44,000,000, from THB 44,000,000 to THB 88,000,000, by issuing 4,400,000 new ordinary shares at THB 10 par value for working capital.

  • Incorporated SNP-Novion Holding Co., Ltd. (now Specialty Natural Innovation Co., Ltd.) with THB 44,880,000 registered capital on 2 October 2003, to operate as an investment holding company. Specialty Holding Co., Ltd. acquired shares in Specialty Natural Products Co., Ltd. through this capital increase.

2,007
  • SNPS began expanding its customer base internationally into East Asia, Southeast Asia, and Europe.

2,009
  • The Company obtained ISO 9001:2008 certification from SGS (Thailand), an internationally recognized quality management system standard.

  • The Company obtained Organic Agriculture product certification from Organic Agriculture Certification Thailand.

2,012
  • Incorporated Specialty Innovation Co., Ltd. (“SI”) on 16 February 2012 with THB 1,000,000 registered capital, to engage in the manufacturing and distribution of cosmetics and cosmeceuticals, dietary supplements, and traditional medicines.

2,013
  • SNPS increased registered capital by THB 182,000,000, from THB 88,000,000 to THB 270,000,000, by issuing 18,200,000 new ordinary shares at THB 10 par value for working capital (April). Subsequently in September, the Company further increased registered capital by THB 13,300,000, from THB 270,000,000 to THB 283,300,000, by issuing 1,330,000 new ordinary shares at THB 10 par value for working capital.

  • SI increased registered capital by THB 89,000,000, from THB 1,000,000 to THB 90,000,000, by issuing 890,000 new ordinary shares at THB 100 par value, to support the expansion of the health, beauty, and hygiene product business.

2,016
  • The Company received an Honorable Mention Award for SME Industry Management from the Ministry of Industry.

  • SI obtained ISO 22716:2007 certification from SGS (Thailand), the international standard for Good Manufacturing Practices for cosmetics.

  • SI obtained ISO 9001:2008 certification from SGS (Thailand), an internationally recognized quality management system standard.

  • SI obtained HALAL certification from the Central Islamic Council of Thailand.

2,017
  • SI registered as a medical device manufacturing establishment with the Food and Drug Administration (FDA), Ministry of Public Health, covering the production of Nursing Services medical devices.

  • The Company received the national-level Prime Minister Herbal Awards (PMHA) 2017 in the Small and Medium Enterprise (SME) category.

  • SI obtained LEED (Leadership in Energy and Environmental Design) GOLD certification from the U.S. Green Building Council (USGBC), becoming the only health and beauty product manufacturer in Thailand to receive this certification

2,018
  • The Company obtained Green Industry Level 2 certification from the Ministry of Industry.

  • The Company obtained ISO 9001:2015 certification from SGS (Thailand), an internationally recognized quality management system standard.

  • The Company received the Rice Plus Award 2018 from the Department of Foreign Trade for the development of Black Glutinous Rice Extract Liquid.

  • The Company received the Thailand Trust Mark (T Mark) from the Department of International Trade Promotion, certifying quality products manufactured in Thailand.

  • SNPS jointly with its major shareholders incorporated Kanae Innovation Co., Ltd. (“KI”) on 7 November 2018 with THB 1,000,000 registered capital for the packaging business, as a joint venture with Kanae Company Limited, a full-service packaging manufacturer from Japan.

  • KI increased its registered capital by THB 34,000,000, from THB 1,000,000 to THB 35,000,000, by issuing 3,400,000 new ordinary shares at a par value of THB 10 per share for working capital.

2,019
  • SNPS reduced registered capital by THB 38,300,000, from THB 283,300,000 to THB 245,000,000, at a par value of THB 10 per share, to optimize its capital structure.

  • SNPS further reduced registered capital by THB 97,000,000, from THB 245,000,000 to THB 148,000,000, at a par value of THB 10 per share, to optimize its capital structure.

  • The Company expanded the scope of its HALAL certification from the Central Islamic Council of Thailand by adding herbal extracts in powder and liquid forms, vitamins, and oils.

  • SI received the Outstanding Herbal Product Selection Award (PMHA) 2019 from the Institute of Thai Traditional Medicine, Department of Thai Traditional and Alternative Medicine, Ministry of Public Health, for the House of Herb Fragrance Diffuser product in Wild Orchid and Sandalwood scents.

  • SI received the National Innovation Award (NIAWARDS) 2019 from the National Innovation Agency (Public Organization) for the 8CT Special Coconut Oil Dietary Supplement product.

  • SI received Winner of Innovative Product from the Thai Agricultural Products Award (Agri Plus Award) 2019 for the Cleanradex Eyelid Hygiene Solution in the marketed non-food category.

  • SI received the Thai Agricultural Products Award (Agri Plus Award) 2019 for the 8CT Dietary Supplement Product in the food category, and the Hivea Moisturising and Nourishing Cream in the research-backed non-food category.

  • SI received the Inventor Awards – Economics Category for the Cleanradex Eyelid Hygiene Solution from the National Innovation Cooperation Project (7Inventor Awards).

2,020
  • SI received FDA Quality Awards 2020 – Pharmaceutical Establishment Category from the Food and Drug Administration, Ministry of Public Health.

  • SI received Creator Awards – Economics Category for 8CT Special Coconut Oil Dietary Supplement from the 7Inventor Awards project.

2,021
  • SNPS jointly established Wellnovations Co., Ltd. (“WELL”) on 28 April 2021 with THB 1,000,000 registered capital as a JV with NSTDA Holding Co., Ltd. for consumer innovation product sales.

  • In November 2021, WELL increased registered capital to THB 50,000,000 (SNPS 70%, NSTDA Holding 30%).

  • SI received ESQR’s Quality Convention Dubai 2021 award for outstanding quality, innovation, and ethical integrity.

  • SI received Quality Herbal Product Award 2021 (2nd time) from the Department of Thai Traditional and Alternative Medicine.

2,022
  • The Extraordinary General Meeting of Shareholders No. 1/2022, held on 28 September 2022, resolved to approve the increase of registered capital by THB 152,000,000, from THB 148,000,000 to THB 300,000,000.

  • SNPS increased its investment in SI’s registered capital by THB 50,000,000, from THB 90,000,000 to THB 140,000,000, by issuing 500,000 new ordinary shares at a par value of THB 100 per share for use as working capital.

  • SI obtained Good Hygiene Practice (GHP) and FSSC 22000 certifications from SGS (Thailand), internationally recognized food safety production standards.

  • SI received the Quality Herbal Product Award 2022 for dietary supplement products: Black Galingale Extract (Doctor Nai brand), Richills (Doctor Nai brand), Nine Herb Green Balm for Relief of Itching (Alrise brand), and Andrographis Paniculata Extract Capsule (Madam Thai Herb brand) from the Department of Thai Traditional and Alternative Medicine.

2,023
  • WELL increased its registered capital by THB 16,663,000, from THB 50,000,000 to THB 66,663,000, by issuing 1,666,300 new ordinary shares at a par value of THB 10 per share, offered to Search Entertainment Co., Ltd. (“SEARCH”). Following this transaction, SEARCH held 25.00% of all issued and paid-up shares, while the Company and Nastda Holding Co., Ltd. held 52.50% and 22.50%, respectively.

  • The Extraordinary General Meeting of Shareholders No. 2/2023, held on 25 July 2023, resolved to approve the following:

    • Conversion of the Company to a public company limited

    • Change of par value from THB 10 per share to THB 1 per share

    • Increase of registered capital by THB 105 million, from THB 300 million to THB 405 million

2,024
  • KI increased its registered capital by THB 5,000,000, from THB 35,000,000 to THB 40,000,000, by issuing 500,000 new ordinary shares at a par value of THB 10 per share for use as working capital.

  • SNPS was listed on the Stock Exchange of Thailand under the ticker symbol “SNPS” on 29 November 2024.

  • The Company received the Prime Minister’s Industry Award 2024 for Outstanding Small and Medium Industry in two categories: Global Business Management and Creative Product Development.

  • The dietary supplement product Colosure under the Wellnova brand received the following awards:

    • Inventor Awards — Economics Category, from the National Innovation Cooperation Project (7Inventor Awards)

    • Gold Medal at the 17th International Inventor and Innovation Contest (INTARG 2024) in Poland

    • NRCT Special Award from the National Research Council of Thailand (NRCT)

2,025
  • SNPS obtained Good Herbal Processing Practice (GHPP) certification for herbal raw material production in accordance with ministerial regulations, an important standard certifying the quality and safety of herbal production processes under criteria established by the Ministry of Public Health.

  • SNPS obtained ECOCERT COSMOS (APPROVED) certification for raw materials verified as compliant with COSMOS-certified cosmetics standards, confirming that these raw materials are free from harmful chemicals or substances contrary to COSMOS sustainability principles.

  • SI obtained Green Industry Level 3 certification, demonstrating systematic environmental management with monitoring, evaluation, and a continuous improvement cycle.

  • SNPS obtained Organizational Carbon Footprint certification (Ref: Carbon Label Registration Announcement, TGO Board Meeting No. 1/2025, dated 24 February 2025).

  • SNPS obtained Organizational Carbon Footprint certification (Ref: Carbon Label Registration Announcement, TGO Board Meeting No. 2/2025, dated 8 October 2025).

  • SI obtained Organizational Carbon Footprint certification (Ref: Carbon Label Registration Announcement, TGO Board Meeting No. 2/2025, dated 24 March 2025).

  • SI’s dietary supplement product Athis (Athis Amrit brand) was awarded a Gold Medal at the 2025 Japan Design, Idea and Invention Expo (JDIE 2025), organized by the World Invention Intellectual Property Associations (WIIPA) in Tokyo, Japan.

  • SI’s dietary supplement product Collatis was awarded a Gold Medal at The 49th Inova — International Invention Show (INOVA 2025) in Croatia.

Use of Proceeds from Securities Offerings

Is There Money Raised from a Securities Offering Still to Report On?

No

Commitments Made in the Registration Statement

Are There Commitments or Conditions from an Offering or Listing?

No

Group Operating-Structure Policy

Description

The Company has established a division of operations among Group companies in accordance with the objectives of each company’s incorporation, as detailed below:

1. Specialty Innovation Co., Ltd. (“SI”)

SI was incorporated on 16 February 2012 with a registered capital of THB 1 million, divided into 10,000 ordinary shares with a par value of THB 100 per share. SI has increased its capital on a continuous basis, and as of 2022, SI has a registered capital of THB 140 million, divided into 1,400,000 ordinary shares with a par value of THB 100 per share. The Company holds 99.53% of SI’s total issued and paid-up shares, with the remaining 0.47% held by SNI. SI engages in the manufacturing and distribution of health, beauty, and hygiene products, comprising cosmetics and cosmeceuticals, dietary supplements, herbal products, and medical products, in both the contract development and manufacturing of products under customers’ brands (Original Design Manufacturer: ODM) and the manufacturing and distribution of products under the Group’s brands (Original Brand Manufacturer: OBM).

2. Kanae Innovation Co., Ltd. (“KI”)

KI was incorporated on 7 November 2018 by the Krisdaphong family with a registered capital of THB 1 million, divided into 100,000 ordinary shares with a par value of THB 10 per share. In June 2024, KI increased its registered capital by THB 5 million, bringing the total registered capital to THB 40 million. The Company holds 80.00% of KI’s total issued and paid-up shares. KI engages in the distribution of biomass-based foil sachets, as a joint venture with Kanae Company Limited, a full-service packaging manufacturer and distributor in Japan. Kanae Company Limited will disclose and transfer knowledge of COSMOPACK technology by providing technical assistance and will procure COSMOPACK filling machines for KI. In addition, Kanae Company Limited and Approved Packaging Suppliers will supply packaging raw materials to KI at agreed prices.

3. Wellnovations Co., Ltd. (“WELL”)

WELL was incorporated on 28 April 2021 by the Kritsadapong family. Currently, WELL has a registered capital of THB 66,663,000, divided into 6,666,300 ordinary shares with a par value of THB 10 per share. The Company holds 52.50% of WELL’s total issued and paid-up shares.

WELL engages in the distribution of herbal innovation products under the Group’s trademarks, with its main products being the Complete Formula Closure (Colosure) dietary supplement under the Wellnova brand. The joint venture in WELL has the objective of generating growth and serving as a platform for bringing research outputs of research agencies and partners to commercial markets. Each joint venture partner has agreed to support the following:

  • SNPS shall be responsible for product manufacturing and distribution, business administration, facilitation of product development, and related services.

  • NSTDA shall facilitate the linkage of research and development and related support services of the National Science and Technology Development Agency.

  • The Harnpanich group shall support product sales, particularly the distribution of products through hospital channels.

Companies Where the Company Holds ≥10%

Companies (≥10% Holding)

Company NameAddressProvinceZip CodeTelephoneBusiness TypeSecurity TypeSharesPaid-up Shares
Specialty Innovation Co., Ltd.9 Moo 21, Bang Phli Yai Subdistrict, Bang Phli DistrictSamut Prakarn10540023-133456SI Manufacturing and distribution of health, beauty, and hygiene productsCommon shares1,400,000140,000,000
Kanae Innovation Co., Ltd.9 Moo 21, Bang Phli Yai Subdistrict, Bang Phli DistrictSamut Prakarn10540023-133456Distribution of biomass-based foil sachet packaging; JV with Kanae Company Limited, JapanCommon shares4,000,00040,000,000
Wellnovations Co., Ltd.9 Moo 21, Bang Phli Yai Subdistrict, Bang Phli DistrictSamut Prakarn10540023-133456Distribution of herbal innovation products under the Group’s trademarks; main product: Complete Formula Closure (Colosure) under Wellnova brandCommon shares6,666,30066,663,000
L-Sola 3 Co., Ltd.102 Na Ranong Road, Khlong Toei, 10110023-133456Electricity generation and transmissionCommon shares10,000,00010,000,000

Shareholders with Potential Conflict of Interest

Has Potential-Conflict Shareholder (Y/N)

No

Relationships Among Major Shareholders

Relationship Exists (Y/N)

No

Shareholders' Agreement

Agreement Exists (Y/N)

No

Shareholding Diagram (Group Structure)

Does the company hold shares in other companies?

Yes

Subsidiaries

Company NameJuristic Persons / Holders
Specialty Innovation Co., Ltd.Specialty Natural Products Public Company Limited · Voting rights percent: 99.53 · Shareholding proportion percent: 99.53
Kanae Innovation Co., Ltd.Specialty Natural Products Public Company Limited · Voting rights percent: 80.0 · Shareholding proportion percent: 80.0 · Kanae Company Limited · Voting rights percent: 20.0 · Shareholding proportion percent: 20.0
Wellnovations Co., Ltd.Specialty Natural Products Public Company Limited · Voting rights percent: 52.5 · Shareholding proportion percent: 52.5 · National Science and Technology Development Agency · Voting rights percent: 22.5 · Shareholding proportion percent: 22.5 · Ms. Pornlak Harnpanich · Voting rights percent: 8.34 · Shareholding proportion percent: 8.34 · Ms. Pornsuda Harnpanich · Voting rights percent: 8.33 · Shareholding proportion percent: 8.33 · Mr. Kantaporn Harnpanich · Voting rights percent: 8.33 · Shareholding proportion percent: 8.33

Associated Companies

Company NameJuristic Persons / Holders
L-Sola 3 Co., Ltd.Specialty Natural Products Public Company Limited · Voting rights percent: 0.0 · Shareholding proportion percent: 0.0 · Specialty Innovation Co., Ltd. · Voting rights percent: 26.0 · Shareholding proportion percent: 26.0

Income Structure

Product / Service Income

CategoryDescriptionThis YearThis Year %Last YearLast Year %2 Years Ago2 Years Ago %
Total revenue from operationsTotal revenue from operations571,702.91100474,673.51100368,090.87100
Revenue from sales 542,742.3494.93450,560.4194.92353,587.3496.06
Revenue from services 11,467.872.016,745.991.423,114.670.85
OtherOthers17,492.73.0617,367.113.6611,388.863.09

Export Income

CategoryDescriptionThis YearThis Year %Last YearLast Year %2 Years Ago2 Years Ago %
Total revenueTotal revenue571,702.91100474,673.51100368,090.87100
DomesticDomestic525,905.0291.99420,913.6588.67331,27290
InternationalInternational28,305.194.9536,892.767.7736,818.8710

Other Income

Operating Other IncomeNon-Operating Other IncomeShare of Profit
1710 · As of year: 17492.7 · Description: Total other income · As of yesteryear: 17367.1 · As of year before yesteryear: 11388.86 · 1711 · As of year: 17492.7 · Description: Other income from operations · As of yesteryear: 17367.1 · As of year before yesteryear: 11388.861712 · As of year: 0.0 · Description: Other income not from operations · As of yesteryear: 0.0 · As of year before yesteryear: 0.01713 · As of year: 160.51 · Description: Share of profit · As of yesteryear: 153.81 · As of year before yesteryear: 210.93

Product / Service Characteristics

Business Type

3114

Business Groups

Business GroupDescription
Standardized Herbal Extract Business (API)

The SNPS Group (“the Company”) manufactures and distributes standardized herbal extracts (Active Phyto-Ingredients, or API) used as raw materials for the dietary supplement, food, cosmetics, and health product industries. Operations cover the entire value chain from sourcing quality herbal raw materials from certified cultivation sources, extraction, quality control, through to product development tailored to specific customer requirements.

The Company has deep expertise in Thai botanicals developed over more than 25 years, focusing on producing extracts with consistent quality, safety, and efficacy. This is achieved through scientific knowledge, advanced extraction technology, and quality control systems conforming to international standards, building confidence among domestic and international customers. The Company also emphasizes developing products aligned with long-term trends in health and sustainability.

Health, Beauty, and Hygiene Product Business

The Group manufactures and distributes health, beauty, and hygiene products through two main business lines:

(a) Original Design Manufacturer (ODM): perated by Specialty Innovation Co., Ltd. (“SI”), the Company’s subsidiary, providing one-stop service for health, beauty, and hygiene products covering consultation, formula design and development, raw material selection, product registration, quality control, and industrial-scale manufacturing. As of end-2025, the Group had more than 1,500 ODM product SKUs in production covering dietary supplements, cosmetics, and healthcare products, with 280+ ready-to-use formulations.

(b) Original Brand Manufacturer (OBM): perated by Wellnovations Co., Ltd. (“WELL”), focusing on developing and marketing differentiated, high-value health, beauty, and hygiene products based on deep R&D. Key products include the Colosure dietary supplement under the Wellnova brand.

Research & Development

Has R&D Policy (Y/N)

Yes

R&D Cost — Description

The majority of R&D expenditure comprises personnel-related costs, accounting for over 60% each year. The remainder consists of other expenses, including analytical testing and inspection fees, equipment depreciation, and various research-related consumables.

With a vision to continuously and sustainably advance technology and innovation, the Company places importance on investment in research and development (R&D) as a critical mechanism for strengthening competitiveness and supporting long-term growth. Over the past 3 years, the Company has continuously allocated R&D budgets to serve as the foundation for driving innovation, developing products, and enhancing the ability to adapt to changes in the industry and market demands.

The Company conducts R&D investment under the following key approaches:

1. Innovation Development for Sustainable Growth

The Company collaborates with research institutions and leading universities to develop new technologies and products capable of meeting future market demands, with a focus on creating innovation-based differentiation and enhancing competitiveness, as well as developing the capabilities of the internal research team to support the Company’s long-term growth.

2. Efficient R&D Budget Management

The Company’s R&D investment is subject to planning, cost-benefit evaluation, and continuous performance monitoring processes to ensure that budgets are allocated to projects with commercial development potential and that can create added value for the organization efficiently.

3. Linking R&D with Corporate Growth Strategy

R&D expenditure is integrated with the Company’s business strategy, with a focus on developing core technology platforms that support market expansion both domestically and internationally, which strengthens competitiveness, maintains industry leadership, and supports continuous customer base expansion.

R&D Cost — Label

Research and development (R&D) expenses over the past 3 years (Million Baht)

R&D Cost — This Year

29930.66

R&D Cost — Last Year

23856.02

R&D Cost — 2 Years Ago

22002.07

Assets Used in the Business

Permanent Assets — Description

The Group has key fixed assets used in business operations, with a total net book value after accumulated depreciation, as shown in the consolidated financial statements as at 31 December 2025, totaling THB 226.10 million, with details as follows:

Permanent Assets — Appraisal

AssetOwnershipObligationAppraisal ValueDescription
LandFreeholdMortgaged with commercial bank87,848,125
Land and buildings NBV THB 162.24M (2025) and THB 168.92M (2024) pledged as collateral for secured credit facilities and bank guarantees
Buildings and improvementsFreeholdMortgaged with commercial bank74,396,121
Land and buildings NBV THB 162.24M (2025) and THB 168.92M (2024) pledged as collateral for secured credit facilities and bank guarantees
Machinery and factory equipmentFreeholdMortgaged with commercial bank47,915,854
Long-term loans fully repaid; currently in process of releasing machinery used as collateral
Factory tools and equipmentFreeholdNo encumbrance4,210,686
Furniture, fixtures and office equipmentFreeholdNo encumbrance6,247,535
VehiclesFreeholdNo encumbrance5,485,951

Intangible Assets — Description

The Group has intangible assets comprising computer software and research rights, with a total net book value after accumulated amortization per the consolidated financial statements as at 31 December 2025 of THB 5.52 million, with details as follows:

Intangible Assets — Appraisal

AssetTypeAppraisal Value
Computer softwareSoftware5,200,156
Research rightsPatent323,287

Has Subsidiaries Investment Policy (Y/N)

Yes

Subsidiaries Investment Policy — Description

The Company has a policy to invest in companies that are aligned with the Company’s objectives, vision, and growth strategy, which would result in increased operating results or profits for the Company, or to invest in businesses that create synergy for the Company, in order to enhance competitiveness and to enable the Company to achieve its objective of becoming a leading operator in its core business. The Company, its subsidiaries, and/or associates may consider making additional investments in other businesses to achieve attractive returns on investment. Investment decisions by the Company, its subsidiaries, and/or associates shall be subject to feasibility analysis, potential assessment, and investment risk evaluation through appropriate investment analysis procedures, which must be approved by the Executive Committee meeting and/or the Board of Directors’ meeting and/or the shareholders’ meeting (as the case may be). The approval of investments in subsidiaries and/or associates must comply with relevant laws, regulations, and announcements. In addition, the Company shall appoint its representatives to serve as directors and executives in subsidiaries and/or associates in proportion to at least its shareholding in such subsidiaries and/or associates, to oversee and ensure that the operations of subsidiaries and/or associates are aligned with the Company’s policies.

Marketing Policy & Competition

Reporting Mode

3117

Marketing Policy (Overall)

The Group operates under the vision “Partnering with Nature, Empowering Growth”, focusing on the development of Active Phyto-Innovation—innovative plant-based extracts—to create quality products that promote good health sustainably. The Group has established four core business strategies as follows:

1. Emphasis on Research and Development to Create Product Differentiation

The Group focuses on continuous research and development to create products that are distinctive and supported by scientific evidence, in order to build competitive advantages in the global market.

In 2025, the Company invested THB 29.93 million in R&D, an increase from THB 23.86 million in the previous year, or an increase of 25.46%, reflecting the Company’s commitment to innovation development and enhancement of long-term competitiveness.

In addition, the Company has carried out research collaborations with external agencies and leading research institutions, including:

  • The Thai Red Cross Society and King Chulalongkorn Memorial Hospital, for the development of SALYWA artificial saliva gel for cancer patients with dry mouth conditions, which has been registered as a petty patent and helps improve patients’ quality of life.

  • The National Science and Technology Development Agency (NSTDA), for the development of herbal products with high commercial potential.

  • The Faculty of Medicine Siriraj Hospital, Mahidol University (SICRES), to support clinical research and strengthen the scientific evidence base of herbal extract products.

In 2025, the Company developed the following key product innovations:

  • NaturBrill — natural color innovations from Thai plants, comprising Rose Red (roselle), Royal Blue (butterfly pea), and Yellow Sunrise (Cape jasmine), for the food and health beverage industry.

  • Nior BGF — anthocyanin extract from biotechnology-fermented black sticky rice, which can be used in the cosmetics and healthcare product industries.

    2. Expanding the Customer Base to High-Growth Markets

The Group focuses on expanding into customer segments with high growth potential, including:

  • Medical partners and healthcare facilities (Medical Partners)

  • Preventive health and wellness products (Preventive Health & Wellness)

  • Food additives, particularly natural plant-based colors (Natural Food Additives)

The Company launched natural color products under the NATUREBRILL brand, developed from Thai plants, in response to the continuously growing global demand for natural colors in the food industry.

In addition, the Company participated continuously in major international trade shows and academic conferences, including Vitafoods Europe, ICI Indonesia, VIV Asia, Cosmoprof CBE ASEAN, Fi Asia Thailand, Vitafoods Asia, in-cosmetics Asia, NanoThailand, and Cosmoprof Asia, to build awareness in the global market and expand business partner networks.

Currently, the Company has commenced product distribution through partner networks and distributors in 10 countries: India, Indonesia, Malaysia, Vietnam, Singapore, Australia, New Zealand, Japan, France, and Taiwan.

3. Developing Commercially Ready Innovation Products

The Group places importance on developing Branded Ingredients and intellectual property (IP) supported by scientific evidence, to enable rapid commercialization in the form of Active Phyto-Ingredients and product formulations developed to meet international standards.

Key innovation products include:

  • BGold — nanotechnology-level Kaempferia parviflora (black ginger) extract with clinical studies demonstrating efficacy in skin cell protection and collagen stimulation.

  • Closure — a dietary supplement under the Wellnova brand that received the INTARG Gold Medal 2024 from Poland.

  • GuVnis Gold — a nanotechnology dietary supplement for holistic health, co-developed with the National Science and Technology Development Agency (NSTDA).

    4. Sustainable Supply Chain Management

The Company places importance on developing the supply chain from upstream to downstream, to enable efficient herbal raw material management, reduce risks from seasonal fluctuations, and support the maintenance of the business’s gross profit margins.

In terms of sustainable development, the Company has obtained the following key certifications:

  • Carbon Footprint for Organization (CFO) in February 2025, reflecting its commitment to conducting business under ESG principles.

  • Green Industry Level 3 (Green System) certification from the Ministry of Industry.

In addition, the Company has implemented the “Thankhun Thai Farm” program to build a collaborative network with farmers across more than 15 provinces nationwide through a Partnership Farming system, which helps improve the quality of life of Thai farmers while securing a sustainable supply of herbal raw materials for the Company.

Industry & Competition (Overall)

The Group operates in three main industries that continue to exhibit sustained growth: the herbal and pharmaceutical product industry, the cosmetics industry, and the dietary supplement industry. All three industries are driven by structural factors that support long-term growth.

1. Herbal and Pharmaceutical Product Industry

Global Herbal Extract Market: The global herbal extract market was valued at approximately USD 48.90 billion in 2025 and is projected to grow to USD 103.55 billion by 2034, representing a compound annual growth rate (CAGR) of 8.69%.

Region

Market Share 2024

Value 2024 (USD bn)

CAGR 2025–2034

Asia-Pacific

53%

22.99

8.81%

Europe

22%

9.56

7.5%

North America

14%

6.09

8.0%

Latin America, Middle East and Africa

11%

4.78

7.2%

Source: Industry Market Research

Structural Drivers: The Asia-Pacific region commands the highest market share and is expected to maintain its leadership due to its rich biodiversity and wide variety of herbal plant species. Key countries such as China, India, Japan, and South Korea have centuries-old traditions of herbal use and traditional medicine, along with advanced manufacturing capabilities for herbal extracts and raw materials for health products.

Thailand Situation: Thailand is considered a country with significant advantages and market opportunities arising from the natural product trend, given that Thailand has more than 1,800 herbal species that can be utilized for industrial applications.

Government Policies Supporting the Thai Herbal Industry

2nd National Herbal Action Plan (2023–2027)

The Cabinet approved the 2nd National Herbal Action Plan 2023–2027 on 31 January 2023, with the Department of Thai Traditional and Alternative Medicine as the lead agency. The Plan comprises 5 strategies linking development throughout the value chain from upstream, midstream, to downstream, with the following key outcome indicators:

  • Registered herbal products to increase by at least 10% by 2027

  • Herbal medicine prescriptions in the public health system to increase by at least 10%

  • At least 50 herbal medicines to be included in the National List of Essential Medicines

National List of Essential Herbal Medicines (2nd Edition), 2025

The National Drug System Development Committee announced the National List of Essential Herbal Medicines, 2nd Edition, 2025, on 12 March 2025, to drive and promote the use of herbal medicines in the healthcare system in a concrete manner. This List aims to enable Thai traditional medicine practitioners, applied Thai traditional medicine practitioners, and modern medicine physicians in hospitals to systematically prescribe herbal medicines, in order to strengthen the country’s pharmaceutical security.

The National Herbal Policy Committee approved an integrated plan to bring herbs into economic development, under the collaboration of 6 key ministries: the Ministry of Public Health, Ministry of Commerce, Ministry of Industry, Ministry of Agriculture and Cooperatives, Ministry of Interior, and the Ministry of Higher Education, Science, Research and Innovation. The plan aims to develop the herbal industry throughout the value chain in all dimensions, from cultivation and herbal raw material management, research and innovation development, processing and value addition, to marketing promotion and building Thai herbal brands in the international market. The meeting also approved a 3-year plan (2025–2027) to drive the development of the Thai herbal SME industry, to strengthen competitiveness in both domestic and international markets, together with the establishment of the Key Message “Think Wellness Think Thai Herb” as the unified direction for promoting Thai herbs and herbal products to the global market.

In terms of the global market context, data from Euromonitor International indicates that the global retail value of herbal products stood at USD 60,589.8 million in 2024, with a continuously growing trend projected to reach USD 78,395.6 million by 2029, pointing to significant trade opportunities and the potential for Thai herbal industry market expansion on the international stage.


2. Cosmetics Industry

In 2024, the global Clean Beauty market was valued at approximately USD 9.38 billion and is projected to expand to USD 49.46 billion by 2032, with a CAGR of 14.99%. This growth reflects rising consumer demand for products free from harmful chemicals, that are sustainable, and that use ethically sourced raw materials.

Product Category

Market Share 2024

CAGR 2025–2032

Key Drivers

Skincare

41.70%

14.0%

Demand for natural anti-aging ingredients

Hair Care

25.50%

15.2%

Sulfate-free and paraben-free formulations

Color Cosmetics

18.80%

15.4%

Biotech innovation and social media

Others

14.00%

12.0%

Oral care and fragrance products

Source: Fortune Business Insights, Grand View Research 2024

Key Industry Trends

Consumers worldwide are increasingly aware of the health risks potentially arising from the use of chemicals in conventional cosmetics, which is the primary factor driving demand for safer product alternatives. In addition, stricter international regulations serve as a significant driving force, such as the European Union’s Green Claims Directive, which requires operators to provide verified evidence to substantiate environmental claims and is expected to take full effect by 2026, as well as the U.S. FDA’s Modernization of Cosmetics Regulation Act (MoCRA), which mandates manufacturers to report serious adverse events from product use. These regulatory measures result in companies with robust safety surveillance systems and transparency having a significant competitive advantage in the market.


3. Dietary Supplement Industry

Longevity and Preventive Wellness Market: The global Longevity and Preventive Wellness market was valued at approximately USD 5,827.5 billion in 2024 and is projected to grow to USD 8,505.0 billion by 2030, representing a CAGR of 6.5%, reflecting the shift in consumer behavior from treatment to prevention.

Market Segment

Value 2024 (USD bn)

Value 2034 (USD bn)

CAGR

Longevity Supplements

10.70

20.20

7.1%

Anti-Aging Supplements

4.47

6.99

7.89%

Healthy Aging Supplements

1.53

2.20

7.5%

Longevity & Anti-Aging Drugs

19.18

58.43

11.9%

Source: Grand View Research, Precedence Research, Intent Market Research 2024–2025

Aging Society and Business Opportunities: According to the World Health Organization (WHO) and the United Nations, the global population is aging rapidly. By 2030, it is projected that 1 in 6 people worldwide will be aged 60 years or over. The population aged 60+ is expected to increase from 1,000 million in 2020 to 2,100 million by 2050. This demographic shift is occurring in both developed and emerging markets and is correlated with a higher prevalence of chronic diseases and increasing demand for health, nutrition, and elderly care.

For Thailand, the country entered an Aging Society in 2005, with the population aged 60 and over exceeding 1 in 10. Thailand subsequently entered a Complete-Aged Society in 2021, with the population aged 60 and over exceeding 20% of the total population. It is projected that Thailand will become a Super-Aged Society, with the population aged 60 and over exceeding 28%, by 2035.

Knowledgeable Consumer Trends: Modern consumers are increasingly knowledgeable about the aging process and focus on prevention rather than treatment, placing importance on products that are science-backed, clean, and free from contamination. SNPS is able to respond to these needs through its standardized herbal extracts and Branded Ingredients that have undergone research and clinical testing.


Competitive Advantages of the Group

1. Experience and Expertise: More than 25 years in the herbal extract industry, with a farmer network across 15+ provinces through the Thankhun Thai Farm program.

2. International Standard Certifications: ISO 9001:2015, ISO 22716:2007, FSSC 22000, GHPP (Good Herbal Processing Practice), ECOCERT COSMOS APPROVED, Thailand Trust Mark (T Mark), HALAL, and Carbon Footprint for Organization.

3. End-to-End Manufacturing Capability: From upstream to downstream, including 412 extract products and 1,500+ finished products, with 280+ ready-to-use formulations.

4. Awards and Recognition: Prime Minister’s Industry Award, INTARG Gold Medal, NRCT Special Award from the National Research Council of Thailand.

Note: Market data referenced from Fortune Business Insights, Grand View Research, Precedence Research, Intent Market Research, World Health Organization (WHO), Euromonitor

Procurement of Products & Services

Reporting Mode

3117

Procurement (Overall)

The Group places importance on the procurement of quality raw materials that meet appropriate standards, to support the production of plant-based extracts and health, beauty, and dietary supplement products. The Company selects capable raw material manufacturers and distributors that are able to deliver quality raw materials consistently, in compliance with the Company’s quality specifications and delivery timelines.

The Company has prepared an Approved Vendor List to serve as a mechanism for selecting and controlling the quality of raw material manufacturers and distributors. The Research and Development Department is responsible for inspecting and evaluating the quality of raw materials before approving a vendor. The Company reviews vendor performance evaluations every 6 months, taking into consideration the quality of raw materials, consistency of delivery, and delivery track record as the primary criteria.

In addition, the Quality Control Department conducts random inspections of raw materials upon every delivery, to ensure that all raw materials used in the production process conform to the standards specified by the Company. The Company maintains a policy of sourcing raw materials from at least 2 manufacturers or distributors for key raw materials, in order to reduce the risk of dependence on any single supplier. In the past year, the Group did not purchase raw materials from any single manufacturer or distributor exceeding 30% of total raw material procurement value.

1. Herbal Plants

Herbal plants are a key raw material in the Group’s herbal extract production, such as Kaempferia parviflora (black ginger), Ganoderma lucidum (reishi mushroom), Phyllanthus emblica (Indian gooseberry), and Terminalia chebula (chebulic myrobalan). The Company procures herbal plants primarily from domestic sources, selecting from groups of farmers and producers that are reliable and capable of delivering raw materials that meet the Company’s quality standards.

For herbal plants that are used in high volumes and have continuous market demand, the Company procures from its network of farmer partners and community enterprises that have maintained cooperative relationships for more than 10 years, with advance planning and reservation of raw material quantities aligned with the annual production and sales plans.

In addition, the Company has operated the “Thankhun Thai Farm” program since 2010 to support farmer networks and community enterprises across more than 15 provinces nationwide, including Chiang Mai, Lampang, Phitsanulok, Phetchabun, Nakhon Phanom, and Sa Kaew. The Company transfers knowledge in herbal cultivation, harvesting, and processing, to help upgrade the quality of raw materials and add value to Thai herbal plants, while also creating income and long-term stability for farming communities in a sustainable manner.

The herbal plants procured by the Company are mostly in the form of dried herbs, coarsely ground, finely ground, or cut into pieces, to suit the Company’s extract production processes.

2. Herbal Extracts

Herbal extracts are a key raw material used in the production of the Group’s health, beauty, and hygiene products, such as Kaempferia parviflora (black ginger) extract, Phyllanthus emblica (Indian gooseberry) extract, Aloe vera extract, and Centella asiatica (Gotu kola) extract.

The Company procures herbal extracts primarily from domestic manufacturers and distributors. In certain cases involving specialty herbs that the Company cannot extract in-house, or where the volume of use is not substantial, the Company may consider purchasing extracts from external manufacturers for economic efficiency.

However, herbal extracts procured from external sources must undergo quality analysis and may require additional quality improvement processes before being used in the production process, to ensure conformity with the Company’s quality standards before distribution to customers.

Through this raw material procurement system, the Group is able to effectively control the quality of raw materials, reduce supply chain risks, and support the production of quality and safe products in accordance with international standards.

Raw Material Acquisition (Overall)

The Group places importance on the procurement of quality raw materials that meet appropriate standards, to support the production process of plant-based extracts and health, beauty, and dietary supplement products. The Company selects raw material manufacturers and distributors that are capable and reliable, able to deliver raw materials in compliance with quality specifications, quantities, and delivery timelines.

The Company has established systematic processes for selecting and evaluating raw material manufacturers and distributors by preparing an Approved Vendor List to screen and control vendor quality. The Research and Development Department and the Procurement Department jointly consider vendor qualifications before approval, and regularly evaluate and review vendor performance based on raw material quality, delivery consistency, and the ability to comply with the Company’s requirements.

In addition, the Quality Control Department inspects raw materials upon every receipt from manufacturers or distributors, to ensure that raw materials used in the production process conform to prescribed standards. The Company maintains a policy of sourcing raw materials from at least 2 manufacturers or distributors for key raw materials, in order to reduce the risk of dependence on any single supplier.

The Company’s primary raw materials consist of herbal plants and herbal extracts, which are mostly sourced domestically, particularly from farmer networks and community enterprises that have maintained continuous cooperative relationships with the Company. The Company has operated the “Tan Khun Thai Farm” program to support the development of herbal cultivation among farmers in multiple areas throughout the country, while transferring knowledge in cultivation, harvesting, and processing, to obtain raw materials with quality and active compound content meeting prescribed standards.

This approach enables the Company to control the quality of raw materials from the upstream end of the supply chain, supports the production of quality and safe products in accordance with international standards, and strengthens the sustainability of the business ecosystem and farming communities in the long term.

In 2023–2025, the Company did not purchase raw materials from any single manufacturer or distributor exceeding 30% of total raw material procurement value.

Production Policy (Overall)

The Company plans to invest in machinery under future projects, involving investment in machinery with new technology that upgrades herbal extraction to more efficiently draw out the active compounds of natural raw materials. This will result in extracts with higher concentration and purity that can be used in the pharmaceutical industry, which demands highly concentrated active compounds, as well as in the food industry. The new machinery investment will build upon existing machinery by processing standardized extracts produced by the current machinery through the new machinery’s processes to achieve extracts with higher concentration and purity, for distribution to new customer segments. Therefore, this investment will also result in increased utilization of the existing machinery’s production capacity. In addition, the Group continues to seek growth opportunities and business gaps in new markets on an ongoing basis.

Production capacity is calculated based on 14 working hours per day (8 hours regular working time and 6 hours overtime) and 300 working days per year.

Distributors (Overall)

The Company has 1 manufacturer with cumulative purchases exceeding 10%, which has no direct affiliation with the Company and is merely a business partner with a long trading history and high reliability.

The Company maintains a policy of sourcing raw materials from at least 2 manufacturers or distributors to reduce the risk of dependence on any single manufacturer or distributor.

In 2023–2025, the Company did not purchase raw materials from any single manufacturer or distributor exceeding 30% of total raw material procurement value.

Number of Raw-Material Distributors (Overall)

1

Production Capacity (Overall)

ItemUnitUnit (if Other)UsedCapacity
Specialty Natural Products Public Company LimitedOtherskg.53.66245,180
Specialty Innovation Company Limited.Piece37.6820,400,000
Kane Innovation Company Limited.Piece3.111,880,000

Domestic/Overseas Purchase Proportion (Overall)

Raw MaterialSource CountryValue
Raw materials for productionThailand176,728,542
Raw materials for productionOther6,472,234

Projects Under Construction

Has Projects Under Construction (Y/N)

Yes

Description

This project is a strategic collaboration between SNPS and an overseas listed company for the research and development of a dietary supplement product incorporating Thai herbal extracts. The objective is to develop the product formulation, scale up production to an industrial level, and obtain registration approval from the Thai Food and Drug Administration (TFDA) for commercial distribution.

Total Projects

1

Total Project Value

7837000.0

Recognized Value

6204000.0

Remaining / Unrecognized Value

1633000.0

Projects

Project NameValueIncome %Est. YearsEst. MonthsEst. Completion
R&D Project7,837,00079.16272027-09-01

Debentures & Bills of Exchange

Has Debentures (Y/N)

No

Convertible Securities

Has Convertible Securities (Y/N)

No

Contents